Immunotherapy pioneers reveal updated efficacy data of tisagenlecleucel CAR T-cell therapy

(Children's Hospital of Philadelphia) Physician-scientists from Children's Hospital of Philadelphia presented updated efficacy and safety data on Kymriah (tisagenlecleucel, formerly CTL019) -- the first-ever FDA-approved personalized CAR T-cell gene immunotherapy for aggressive blood cancers, at the 60th American Society of Hematology annual meeting, as well as first-of-its-kind research on overcoming CAR T-cell resistance.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news